ELUTIA INC. (ELUT): M&A transaction — Elutia closes $88M sale of BioEnvelope business to Boston Scientific; pivots to NXT-41x

ELUTIA INC.

Closed sale of CIED/BioEnvelope business to Boston Scientific for $88M cash; $80.3M paid at closing, $8M escrowed for 12 months.
Used $27.8M of proceeds to fully repay and terminate SWK Credit Agreement (principal $24.5M plus fees).
Amended Ligand royalty agreement: paid $1.1M accrued royalties; Ligand consented to sale and released security interest in CIED assets.
Company will focus on NXT-41x drug-eluting biomatrix for breast reconstruction; expects launch first half 2027.
Pro forma cash balance ~$57M; Device Protection Business reported as discontinued operations in future filings.

item 1.01 item 2.01 item 7.01 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

ELUTIA INC. completed a disposition involving Boston Scientific Corporation and Cardiac Pacemakers, Inc. (closed 2025-10-01).

Action: disposition
Counterparty: Boston Scientific Corporation and Cardiac Pacemakers, Inc.
Closing: 2025-10-01

Exact text from the filing

On October 1, 2025, the parties completed the sale of the CIED Business.

View on SEC.gov

Browse all m&a transactions →

ELUTIA INC. filing history →

Source: SEC EDGAR

accession 0001104659-25-097561

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.